Compare TRVI & INOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVI | INOD |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | United States | United States |
| Employees | N/A | 3000 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2019 | 1996 |
| Metric | TRVI | INOD |
|---|---|---|
| Price | $13.47 | $93.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | $21.55 | ★ $100.00 |
| AVG Volume (30 Days) | 1.6M | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.91 | 3.37 |
| EPS | N/A | ★ 0.42 |
| Revenue | N/A | ★ $86,775,000.00 |
| Revenue This Year | N/A | $38.42 |
| Revenue Next Year | N/A | $27.03 |
| P/E Ratio | ★ N/A | $228.40 |
| Revenue Growth | N/A | ★ 9.84 |
| 52 Week Low | $5.38 | $33.79 |
| 52 Week High | $16.12 | $114.77 |
| Indicator | TRVI | INOD |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 73.55 |
| Support Level | $13.11 | $40.21 |
| Resistance Level | $13.97 | $93.82 |
| Average True Range (ATR) | 0.81 | 9.49 |
| MACD | -0.13 | 4.56 |
| Stochastic Oscillator | 15.30 | 71.47 |
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.